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Abstract
Background: Pneumococcal meningitis remains a potentially lethal and debilitating disease, mainly due to
brain damage from sustained inflammation. The release of danger-associated molecular patterns (DAMPs),
like myeloid-related protein 14 (MRP14) and high mobility group box 1 protein (HMGB1), plays a major role
in persistence of inflammation. In this study, we evaluated if paquinimod, an MRP14-inhibitor, and an anti-
HMGB1 antibody can improve clinical outcome as adjunctive therapeutics in pneumococcal meningitis.
Methods: We tested the adjuvant administration of paquinimod and the anti-HMGB1 antibody in our pneumococcal
meningitis mouse model assessing clinical (clinical score, open-field-test, temperature) and pathophysiological parameters
(intracranial pressure, white blood cell count in CSF, bleeding area) as well as bacterial titers in blood and brain 24 h after
administration and 48 h after infection. Furthermore, we explored the interactions of these two agents with
dexamethasone, the standard adjuvant treatment in pneumococcal meningitis (PM), and daptomycin, a non-
bacteriolytic antibiotic preventing pathogen-associated molecular pattern (PAMP) release.
Results: Adjunctive inhibition of MRP14 or HMGB1 reduced mortality in mice with PM. This effect was lost
when the two anti-DAMP agents were given simultaneously, possibly due to excessive immunosuppression.
Combining anti-PAMP (daptomycin) and anti-DAMP treatments did not produce synergistic results; instead,
the anti-DAMP treatment alone was sufficient and superior. The combination of anti-HMGB1 with dexamethasone did
not diminish the effect of the former.
Conclusions: DAMP inhibition possesses good potential as an adjuvant treatment approach in PM, as it improves clinical
outcome and can be given together with the standard adjuvant dexamethasone without drug effect loss in
experimental PM.
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Background
Pneumococcal meningitis (PM) is the most common
form of bacterial meningitis in Europe and the USA [1].
It is still among the major causes of death from infec-
tious diseases in adults worldwide, and survivors often
suffer from brain damage and residual neurological defi-
cits [2]. Extensive neutrophilic inflammation following
pneumococcal infection of the meninges contributes
substantially to brain damage [3]. Meningeal inflammation
is triggered upon recognition of pathogen-associated
molecular patterns (PAMP), liberated during pneumococ-
cal autolysis, by pattern recognition receptors expressed
on and in resident immune cells. As a consequence,
neutrophils are recruited to the cerebrospinal fluid (CSF)
[4, 5] and release all their antimicrobial weapons (like
strong oxidants and proteolytic enzymes) into the extra-
cellular space. The neutrophil-derived toxins, together
with bacterial toxins (like pneumolysin and hydrogen
peroxide), can cause stress and damage to host cells [6, 7].
The injured cells release then endogenous alarm signals
(so-called danger-associated molecular patterns, DAMPs;
[8, 9]) that sustain the immune reaction and drive forward
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brain damage even after CSF sterilization by antibiotics
[10]. Such alarm signals are members of the S100 calgra-
nulin family, especially myeloid-related protein MPR14,
and high mobility group box 1 protein (HMGB1) [11, 12].
HMGB1 is a ubiquitously expressed nuclear protein that
stabilizes nucleosome formation and regulates transcription
[13]. In inflammation, it is secreted by immune cells after
stimulation or can be released from dying cells [14, 15].
Once in the extracellular space, it induces and enhances
cytokine synthesis [12], promotes chemotaxis and accumu-
lation of granulocytes [16], and inhibits phagocytosis of
apoptotic leukocytes [17]. It can exert its functions through
both Toll-like receptor and the receptor for advanced glyca-
tion end products (RAGE) activation [18, 19]. Myeloid-
related protein 14 (MRP14), in turn, is expressed and
secreted mainly in myeloid cells in response to microbial
components and inflammatory cytokines but can also be
released from necrotic cells [20, 21]. Extracellular MRP14
can bind to pattern recognition receptors (PRRs), such as
Toll-like receptor 4 (TLR4), and their interaction leads to
the production of pro-inflammatory cytokines [22]. In vitro,
MRP14 was also reported to support chemotaxis, migra-
tion, and antimicrobial activity of neutrophils and to have
direct antimicrobial activity against pathogens [23–26].
We have previously shown that large amounts of
MRP14 and HMGB1 are secreted in the CSF of patients
and mice during acute PM and blockade of their activity
by paquinimod, a MRP14 inhibitor, and ethyl pyruvate
(REPS), and HMGB1 box A protein, HMGB1 inhibitors,
was beneficial in experimental murine pneumococcal
meningitis [27, 28]. Therefore, they may represent prom-
ising targets for adjuvant therapies in PM. Here, we
evaluated the therapeutic efficacy of paquinimod and an
anti-HMGB1 antibody, given alone or in combination,
as adjuvant agents to antimicrobial treatment in a mouse
model of PM and compared them to other adjuvant
agents like dexamethasone and daptomycin.
Methods
Ethics statement
This study was performed in accordance with the
recommendations in the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. The
study protocol was approved by the local committee on
the ethics of animal experiments (permit number 55.2-
1-54-2531-31-09 and -78-12).
Mouse model of pneumococcal meningitis
A well-characterized mouse model of PM was used in
this study [29, 30]. Briefly, adult male C57BL/6 mice
aged 8–16 weeks were clinically examined and scored.
Clinical scoring consisted of a beam balancing test, a
postural reflex test, and the presence of piloerection,
seizures, or reduced vigilance [31]. In healthy animals,
the score is 0 points; 13 points are attributed to termin-
ally ill animals that have to be euthanized due to ethics
within the observation period. Additionally, an open
field test (as described previously [32]) and temperature
measurements were carried out. After clinical scoring,
meningitis was induced by intracisternal injection of 105
colony-forming units of S. pneumoniae type 2 (D39
strain) under short-term anesthesia induced by isoflur-
ane. Mice injected with equal volume of PBS served as
negative controls (n = 8). In total, 100 mice were used in
this study; two of them had to be euthanized immedi-
ately after intracisternal injection due to clinical signs of
brain stem injury caused by the injection procedure. At
21 h after infection, all 98 mice achieved disease scores
between 4 and 9 and were randomly allocated to the
different i.p. treatment groups which were as follows:
antibiotic therapy with 100 mg/kg ceftriaxone in combin-
ation with 100 μg anti-HMGB1 chicken polyclonal
antibody (SHINO-TEST Corporation, n = 8), 10 mg/kg
paquinimod (Active Biotech, n = 8), anti-HMGB1 +
paquinimod (n = 6), 0.5 mg/kg dexamethasone (every 8 h,
n = 9), anti-HMGB1 + dexamethasone (n = 8), 12 mg/kg
daptomycin (n = 6), or anti-HMGB1 + daptomycin
(n = 8). If not otherwise stated, treatments were given
once per day. Administration of ceftriaxone alone (n = 12)
served as positive control, while adjuvant injection with
anti-HMGB1 isotype antibodies (n = 12) or DMSO
(paquinimod vehicle, n = 9) were used as placebo-treated
controls. Adjunctive treatments were injected 5 min
before ceftriaxone injection. All treatments were applied
immediately after one another. At the time when treat-
ment is started, MRP14 and HMGB1 are conceivably
present in the CSF since previous Western blot and ELISA
experiments showed that MRP14 and HMGB1 are
released into the CSF within the first 18 to 24 h post-
infection in murine pneumococcal meningitis [28, 29].
Moreover, MRP14 and HMGB1 were detected in CSF sam-
ples withdrawn from patients with pneumococcal meningi-
tis at the time of admission to the hospital [28, 29].
Twenty-four hours after therapy, animals were blindly
clinically evaluated again. Then, mice were anesthetized
with ketamine/xylazine, and a catheter was placed into the
cisterna magna. CSF samples were withdrawn for the deter-
mination of CSF leukocyte counts and the intracranial
pressure was measured. Subsequently, blood samples were
obtained by transcardial puncture for the assessment of
bacterial titers and total leukocyte counts. After deep
anesthesia induced by thiopental, mice were perfused with
ice-cold phosphate-buffered saline containing heparin.
Brains were removed and frozen immediately. The experi-
ment was performed in batches of 8 mice, with 1–2 mice
randomly allocated to one of the different treatment
groups, so that for every treatment group, the procedure
was repeated at least thrice.
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Determination of bacterial titers in the blood and brain
Cerebella were dissected and homogenized in sterile
saline. Blood samples and cerebellar homogenates were
diluted serially in sterile saline, plated on blood agar
plates, and cultured for 24 h.
Analysis of cerebral bleeding
Mice brains were cut in a frontal plane into 30-μm-thick
sections using a cryotome. Beginning from the anterior
parts of the lateral ventricles (BREGMA 1.3 mm), every
10 sections (300 μm in total), a photograph was taken
with a digital camera throughout the ventricle system to
assess the number and total area of cerebral bleeding.
Nine frames in total were photographed, covering a 2.7-
mm interval in rostral-dorsal direction (up to BREGMA
− 1.4 mm). Per frame, the number of blood spots was
counted and the area of each blood spot was measured
(Image J tool, NIH). From the data acquired, the total
number and total area of blood spots per brain were
calculated and compared.
Statistical analysis
The principal statistical test was one-way ANOVA,
followed by Student-Newman-Keuls post hoc testing.
Differences were considered significant at p < 0.05. Data
are displayed as means. Statistics was conducted with
Prism, Graph Pad software.
Results
In a first experimental series, we tested the efficacy of
paquinimod, anti-HMGB1 antibody, and a combination
of both as adjuvant therapies in our experimental PM
mouse model. Treatment was started 21 h after intracis-
ternal pneumococcal infection. Positive controls received
only ceftriaxone with or without placebo which was a
DMSO solution and/or isotype control antibodies.
(Fig. 1). Mice that were injected intracisternally with
PBS instead of S. pneumoniae served as negative
controls. The overall clinical outcome determined by a
clinical score was better in mice treated adjuvantly with
paquinimod or anti-HMGB1 antibodies, however not in
those treated with their combination (Fig. 1a). This was
also reflected in the mortality rates among the different
treatment groups: in each adjuvant monotherapy group,
all mice survived, whereas the mortality rates in the
positive control groups and the adjuvant combination
therapy group were 25, 25%, 22.2, and 16.7%, respect-
ively (not significant). In other clinical parameters, anti-
HMGB1 led to a significantly better performance in the
open field test in comparison to all other groups, while
paquinimod and the combination of anti-HMGB1 and
paquinimod did not produce significantly better results
than the control groups (Fig. 1a). Considering body
temperature, anti-HMGB1 and paquinimod (mono)
therapy were associated with milder meningitis-associated
hypothermia than that found in positive control groups,
while the combination of anti-HMGB1 and paquinimod
showed body temperatures equal to these control groups.
One possible explanation for the worse clinical outcome
in anti-HMGB1 plus paquinimod-treated mice could be
the significantly lower bacterial elimination from both the
blood and the CNS, as compared to all other infected
groups (Fig. 1b). This, in turn, might be linked to the
observed dramatic reduction in CSF pleocytosis (Fig. 1c).
The latter was also detectable in mice treated with anti-
HMGB1 antibodies or paquinimod alone, however to a
lesser degree (reduction by 58 and 47%, respectively,
versus 76% in the combination group). Of note, the reduc-
tion in intracranial pressure (ICP) observed after com-
bined treatment with anti-HMGB1 and paquinimod was
less pronounced than that found after single administra-
tion of these drugs (Fig. 1c). Strikingly, while anti-HMGB1
performed overall better compared to paquinimod or the
combination of both, it led to an increase in the total
cerebral bleeding area (Fig. 2).
Since the adjuvant monotherapies with paquinimod
and anti-HMGB1 were clearly superior to the combin-
ation therapy and anti-HMGB1 fared clinically slightly
better than paquinimod, we focused in our next experi-
ments on counteracting HMGB1. We addressed the
question whether adjuvant anti-HMGB1 therapy is still
effective when given (hours) after the start of antibiotic
therapy. For this, infected mice were treated with
ceftriaxone 21 h after infection, while 3 h later, mice
received anti-HMGB1 antibodies. All positive effects of
anti-HMGB1 that were seen in the previous experiments
were not seen any more when anti-HMGB1 was given
3 h after antibiotics. For instance, clinical score and
leukocyte count were doubled in the 3 h-post-treatment
group (data not shown). These findings suggest that a
timely administration is required to produce the best
possible protective effect.
Currently, dexamethasone is the only adjuvant with
proven effectiveness in adult patients with pneumococ-
cal meningitis in countries with a high level of medical
care but its effectiveness is far from being perfect. Thus,
the impact of adding anti-HMGB1 to dexamethasone on
the course of PM was assessed. In detail, we wanted to
know whether both substances act in a synergistic
immunosuppressive manner or whether dexamethasone
co-application attenuates the protective effects of anti-
HMGB1, since it has been shown to interfere with drug
penetration to the CNS [33]. Dexamethasone monother-
apy resulted in a slightly improved clinical status (as evi-
denced by significantly lower clinical score values)
compared to untreated or placebo-treated controls (data
not shown). When compared with mice treated with
dexamethasone alone as standard adjunctive treatment,
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mice that received adjunctive anti-HMGB1 performed
significantly better in the open field test and exhibited
lower CSF leukocyte counts as well as ICP values
(Fig. 3a–c). Co-administration of anti-HMGB1 and dexa-
methasone was comparably effective in improving the
disease course as the anti-HMGB1-monotherapy, as in-
dicated by similar clinical score values, motor activities,
body temperatures, ICP values, and CSF leukocyte num-
bers (Fig. 3a, c). Interestingly, the co-administration of
dexamethasone and anti-HMGB1 was associated with a
significant reduction of the extent of cerebral bleeding
as seen in mice who received adjunctive anti-HMGB1
only (Figs. 2 and 3c). Altogether, combining the two
agents had the similar outcome as adjunctive anti-
HMGB1 by itself, implying that dexamethasone does not
interfere with the beneficial effects of anti-HMGB1.
Beta-lactam antibiotics, like ceftriaxone, which belong to
the standard therapeutic regimen in PM trigger the auto-
lytic degradation of pneumococcal cell walls, resulting in an
abrupt release of PAMPs into the CSF, thus boosting the
inflammatory host reaction. Non-bacteriolytic antibiotics
like daptomycin and rifampicin have been proven beneficial
in an infant rat and a rabbit model of PM [34, 35]. There-
fore, we asked whether combining an “anti-PAMP” agent
Fig. 1 a–c Effects of paquinimod and anti-HMGB1 antibodies as adjuvants in the treatment of pneumococcal meningitis (PM). All infected mice
were treated 21 h after infection with ceftriaxone (CFX) except for mice injected with PBS (which served as negative control). DMSO (vehicle for
paquinimod) and isotype antibodies were used as placebo controls. Lumbar puncture and collection of clinical parameters (a), bacterial titers (b),
and pathophysiological parameters (c) were performed 24 h after the start of treatment. The line within each group of points represents the
mean of the group. Statistics were conducted using one-way ANOVA and Student-Newman-Keuls post hoc test. For the blood and cerebellar titer,
the dotted line represents the lower detection limit at log(cfu) = 1. *p < 0.05, compared to PBS; #p < 0.05 compared to positive controls (CFX
alone, CFX + isotype and CFX + DMSO); §p < 0.05 compared to CFX + paquinimod + anti-HMGB1; +p < 0.05 compared to CFX + anti-HMGB1
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(the non-bacterioloytic antibiotic daptomycin) with a
DAMP antagonist (the anti-HMGB1 antibody) could
produce synergistic protective effects in our PM model.
The combination of daptomycin and anti-HMGB1 led to a
clinical outcome similar to that observed after adjunctive
therapy with daptomycin or anti-HMGB1 alone (Fig. 3a).
Bacterial blood titers were comparable in all three
adjunctive treatment conditions (Fig. 3b) and equally low
compared to untreated controls (data not shown), while
cerebellar titers tended to be lower in the combination
therapy group (not significant). There were also no
between-group differences with regard to ICP values and
leukocyte counts in CSF (Fig. 3c). Of note, daptomycin
co-application was capable of dampening the adverse
(side) effect of anti-HMGB1 on the meningitis-associated
increase in cerebral bleeding (Fig. 3c). Overall, concurrent
administration of anti-HMGB1 and daptomycin did not
show synergistic effects in PM, suggesting that PAMP and
DAMP release represents serial events (but not parallel
pathways) in the pathophysiology in PM.
Discussion
Pneumococcal meningitis is still considered a lethal
infectious disease worldwide despite advances in therapy,
due to extensive brain damage caused by sustained
immune response even after the bacteria are eliminated
[1]. We have postulated that the preservation of the
immune reaction is attributed to the release of DAMPs by
injured immune and neuronal cells even long after CSF
sterilization of [27, 28]. Here, we tested if paquinimod, a
known specific MRP14 inhibitor, and an anti-HMGB1 anti-
body have a potential as adjuvant therapies in PM. We
showed (i) that anti-DAMP treatment had an additional
protective effect in PM to the standard antibiotic treatment.
Strikingly, (ii) this effect was lost when combining the two
anti-DAMP agents. (iii) Combining the anti-HMGB1 treat-
ment with dexamethasone, the standard adjuvant treatment
of pneumococcal meningitis, neither improved nor dimin-
ished the effect of the former. Finally, (iv) combining anti-
PAMP (daptomycin) and anti-DAMP treatment did not
produce synergistic results; instead, the anti-DAMP treat-
ment alone was sufficient and superior.
We had previously identified MRP14 and HMGB1 as
two DAMPs playing a significant role in the pathobiol-
ogy of PM and had shown that antagonizing them may
be a promising therapeutic approach [27, 28]. In previ-
ous studies, we used ethyl pyruvate (REPS) and HMGB1
box A protein [27]. Although both agents have been
shown to inhibit HMGB1 function, they were not ideal,
as the former is an unspecific inhibitor of HMGB1
release, while the latter is a reversible competitive antag-
onist of extracellular HMGB1 that displaces HMGB1
binding to cells and thus cannot prevent HMGB1
function entirely [36, 37]. Here, we opted for an anti-
HMGB1 antibody overcoming mentioned obstacles. In
line with the previous data, anti-HMGB1 therapy proved
clinically and pathologically protective in our PM model.
Interestingly, in contrast to ethyl pyruvate and box A,
anti-HMGB1 led to an increased extent of bleeding.
Since the isotype antibody did not produce the same re-
sults, this adverse effect is suggestively the result of the
specific interaction of anti-HMGB1 with its target rather
than an antibody effect. However, the mechanism behind
this side effect remains unknown and should be examined
Fig. 2 Comparison of the extent of cerebral bleeding after various treatments in pneumococcal meningitis (PM). Beginning from the anterior parts of
the lateral ventricles, nine serial sections of brains were photographed with a digital camera in 0.3-mm intervals throughout the ventricle system. Per
frame, the number of blood spots was counted and the area of each blood spot was measured. Depicted are representative examples of the
following treatment groups: PBS (negative control), ceftriaxone (CFX) alone (positive control), anti-HMGB1 and anti-HMGB1 + dexamethasone
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further in future studies. Paquinimod administration
delivered similar protective results as we have previously
observed [28]. When we co-administered paquinimod and
anti-HMGB1 in order to find out whether this approach
could lead to enhanced effectiveness, we strikingly
observed a negation of the positive results of their individ-
ual administration. A possible explanation might be the
significantly higher bacterial titers in the blood and brain
observed in the combination therapy group. Insufficient
bacterial clearance is known to negatively affect the
clinical outcome [38]. The lower bacterial clearance could
be associated with the lower leukocyte counts in CSF [39],
suggesting the need of maintaining a certain threshold of
immune reaction that can assist antibiotic therapy in
pneumococcal elimination.
Since anti-HMGB1 performed slightly better than
paquinimod, we concentrated our studies on the former.
Addressing the question of the time point of the
administration, we observed a considerable attenuation of
the beneficial clinical effect when anti-HMGB1 was given
3 h after antibiotic treatment. This implicates that, even
though HMGB1 is considered a relatively late inflammatory
Fig. 3 a–c Effects of combined administration of anti-HMGB1 antibodies and dexamethasone or daptomycin in the adjuvant therapy of pneumococcal
meningitis (PM). All infected mice were treated 21 h after infection with ceftriaxone; isotype antibodies were used as placebo control. Lumbar puncture
and collection of clinical parameters (a), bacterial titers (b), and pathophysiological (c) parameters were done 24 h after the start of therapy. The line within
each group of points represents the mean of the group. Gray bars represent results already shown in Fig. 1. The treatment groups in gray were compared
to either CFX + dexamethasone and CFX + anti-HMGB1 + dexamethasone or CFX + daptomycin and CFX + anti-HMGB1 + daptomycin. Statistics were
conducted using one-way ANOVA and Student-Newman-Keuls post hoc test. For the blood and cerebellar titer, the dotted line represents the lower
detection limit at log(cfu) = 1. *p < 0.05 compared to CFX + anti-HMGB1; +p < 0.05 compared to CFX + anti-HMGB1 + dexamethasone;
#p < 0.05 compared to CFX + anti-HMGB1 + daptomycin
Masouris et al. Journal of Neuroinflammation  (2017) 14:214 Page 6 of 9
mediator and reaches high levels in the CSF in advanced
disease stages [27, 40], inhibiting its function timely with
the beginning of antibiotics is the essential way to prevent a
prolongation of the immune response and brain damage.
Early administration concurrent or immediately prior to
antibiotics has already been shown for dexamethasone to
have the best possible effect [41, 42] and comprises the
current recommendation for the standard PM treatment
[43]. Since then, all adjuvant approaches tested in animal
models or clinical trials have adopted the concurrent
treatment as with dexamethasone, like daptomycin or
rifampicin [34, 35].
Various adjuvant therapeutic approaches aimed at damp-
ening the inflammatory reaction and protecting the brain
from injury have been evaluated in animal PM models.
Among them, a prominent group of agents are non-
bacteriolytic antibiotics like daptomycin and rifampicin. In
previous studies, those antibiotics led to a similar bacteria
clearance in CSF as ceftriaxone, though causing less inflam-
mation and brain damage by killing bacteria without cell
lysis and thus preventing the release of PAMPs [34, 35].
Since PAMPs and DAMPs are the motors of inflammation
in PM, we combined anti-PAMP (daptomycin) and anti-
DAMP (anti-HMGB1) treatment to investigate if blocking
both pathways produces synergistical effects. Interestingly,
the combination therapy had no additional effects on clin-
ical parameters than HMGB1 alone. These results suggest
that PAMP and DAMP signaling are not parallel pathways
but rather serial events, and blocking the DAMP signaling
pathway alone is pivotal and sufficient to reduce brain dam-
age and improve clinical outcome of PM. In previous stud-
ies, where non-bacteriolytic antibiotics had a substantial
positive effect on clinical outcome, they were given simul-
taneously to up to 1 h before ceftriaxone [35]. The applica-
tion regimen of drugs (e.g., the timing of the administration
of individual drugs) can possibly influence their therapeutic
efficacy. That could also be the case when combining anti-
PAMP and anti-DAMP treatments in bacterial meningitis.
Here, we opted for a simultaneous treatment regimen
having in mind the potential clinical translation. In the
clinical setting, when bacterial meningitis is suspected,
empiric antimicrobial treatment has to be given promptly
and should not be delayed while awaiting (first)
therapeutic effects of potential adjunctive drugs. This is
because early antibiotic treatment is associated with better
outcome [44, 45].
Dexamethasone is to date the only adjuvant with proven
additional clinical benefit and thus the drug of choice for
adjunctive treatment of PM [41, 43]. One well-known prob-
lem for dexamethasone is interference with drug penetra-
tion into the CNS, resulting in lower CSF levels of various
substances, such as vancomycin [46] and daptomycin [33],
which in turn can lead to a lower bacterial clearance and
therapeutic failure. Since adjunctive dexamethasone has
been advocated for adult patients with PM (in high-income
countries) by IDSA and ESCMID guidelines [47, 48], every
other potential agent for adjunctive treatment should not
interact with it in a detrimental manner. Therefore, we
examined the impact of anti-HMGB1 in addition to
adjunctive dexamethasone in our PM model. The protect-
ive activity of adjunctive anti-HMGB1 treatment was not
diminished when combined with dexamethasone, albeit the
two agents did not act synergistically, indicating the
possibility of a co-administration of dexamethasone and
anti-HMGB1 antibodies in PM. Even more relevantly, the
only drawback observed in the treatment with anti-
HMGB1, the increase in the number and total area of
bleeding foci, was counteracted by its combination with
dexamethasone, probably due to improvement of the
blood-brain-barrier [49].
Conclusions
In summary, anti-HMGB1 possesses good potential as an
adjuvant therapeutic strategy in PM, as it improves clinical
outcome and can be given together with the standard
treatment of antibiotics and dexamethasone. Thus, it may
deserve consideration for future clinical studies.
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